NoNO Inc. has taken an aggressive approach towards the development of a comprehensive, worldwide Intellectual Property portfolio. The company takes a three-tiered approach. First, patents covering the basic biology of a drug target and methods for identification of inhibitors are filed. Second, patents on methods of treating disease(s) using compounds identified using first patent technology are filed. Finally, more specific patents to broaden coverage on therapeutics as they advance, including composition of matter patents, formulation patents, dose range patents, and patents for combined use with other methods or drugs are filed. NoNO Inc. currently has and has >95 patents issued or allowed and ~90 US and national phase patents pending.